Industry Symposia
Industry Symposium
Treatment-Resistant Schizophrenia (TRS): will new biological findings lead to novel drug development?
Chair
Peter Falkai
Ludwig Maximilian University of Munich, Germany
Programme
Treatment-resistant schizophrenia (TRS): no progress in almost 40 years
P. Falkai
Ludwig Maximilian University of Munich, Germany
Management of patients with treatment-resistant schizophrenia (TRS) in India
R. Reddy
Help Hospital, Vijayawada, India
Failure of current management in patients with treatment-resistant schizophrenia (TRS)
C. Correll
The Zucker Hillside Hospital, Zucker School of Medicine at Hofstra/Northwell, New York, USA; Charité University Medicine Berlin, Germany
Beyond receptor blockade: New approaches in developing novel atypical antipsychotics
C. Andrade
National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India
Glutamate modulation by evenamide: clinically meaningful benefits and the ENIGMA-TRS phase 3 program
R. Anand, MD
Newron Pharmaceuticals
Q&A and Discussion
